



Acarix Receives Sizeable Patch Reorder from Louisiana Primary Care Clinic

Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, is pleased to announce a significant reorder of single-use patches by a busy primary care clinic in the New Orleans, Louisiana, metropolitan area. These patches will be used with the CADScor System to evaluate symptomatic patients suspected of coronary artery disease (CAD).

Primary care clinics offer comprehensive services to evaluate, diagnose, and treat various health conditions, including heart health. Diagnostics in this setting enable early detection of potential issues and the development of personalized care plans. This proactive approach helps manage risk factors, enhances patient outcomes, and reduces the need for advanced interventions. By providing accessible and consistent care, primary care clinics play a vital role in maintaining overall health and well-being.

"Reorders from primary care clinics highlight the benefits of quickly and easily stratifying patients suspected of coronary artery disease early in the diagnostic pathway with the CADScor System," stated Aamir Mahmood, Acarix President and CEO. "We are pleased to showcase the growing recognition of the system's effectiveness at the point of care before any potential secondary evaluation takes place."

For more information contact:

Jennifer Anderson, Head of Marketing & Communications, phone +1 720 471 4625, email jennifer.anderson@acarix.com

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

Attachments

[Acarix Receives Sizeable Patch Reorder from Louisiana Primary Care Clinic](#)